Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK1987/000080external-prioritypatent/WO1988000210A1/en
Application filed by Novo Nordisk AsfiledCriticalNovo Nordisk As
Publication of FI880852ApublicationCriticalpatent/FI880852A/fi
Publication of FI880852A0publicationCriticalpatent/FI880852A0/fi
Application grantedgrantedCritical
Publication of FI100107BpublicationCriticalpatent/FI100107B/fi
A novel blood coagulation factor IX/factor X-binding protein with anticoagulant activity from the venom of Trimeresurus flavoviridis (Habu snake): isolation and characterization
Characterization of an abnormal fibrinogen Osaka V with the replacement of gamma-arginine 375 by glycine. The lack of high affinity calcium binding to D-domains and the lack of protective effect of calcium on fibrinolysis.
Some anticardiolipin antibodies recognize a combination of phospholipids with thrombin-modified antithrombin, complement C4b-binding protein, and lipopolysaccharide binding protein